DBV Technologies has begun screening the first participant in its phase 2 THRIVE clinical trial to test the VIASKIN Peanut patch on infants aged 6 to 12 months with peanut allergies. The study aims to evaluate the patch's safety and effectiveness in enabling these infants to consume peanuts freely after treatment. Participants will use the patch daily for 36 months, followed by an oral peanut challenge to determine their tolerance and potential peanut consumption for the next year. This trial could lead to early, non-invasive allergy treatment for young children, potentially changing the course of peanut allergies.
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
